Related Experiment Video

Updated: Mar 13, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

4.4K

Data on common variants associated with coronary artery disease/myocardial infarction in ethnic Arabs

Salma M Wakil1, Ramesh Ram2, Nzioka P Muiya1

  • 1Genetics Department, King Faisal Specialist Hospital and Research Centre, Riyadh, KSA, Saudi Arabia.

Data in Brief
|October 21, 2016
PubMed

Insights

This study identified genetic risk factors for coronary artery disease (CAD) and myocardial infarction (MI) in Saudi Arabians. Findings reveal specific genetic loci associated with increased risk for these cardiovascular conditions.

Area of Science:

  • Genetics
  • Cardiovascular Disease Research
  • Population Genetics

Background:

  • Coronary artery disease (CAD) and myocardial infarction (MI) are significant global health concerns.
  • Understanding the genetic underpinnings of CAD/MI in diverse populations is crucial for targeted interventions.
  • Previous genetic studies have primarily focused on European cohorts.

Purpose of the Study:

  • To conduct a genome-wide association study (GWAS) to identify genetic susceptibility loci for CAD and MI in a large Saudi Arabian cohort.
  • To validate identified loci in an independent sample set.
  • To investigate the genetic ancestry of the Saudi cohort in relation to other populations.

Main Methods:

  • Genome-wide association study (GWAS) utilizing the Affymetrix Axiom Genotyping platform.
  • Analysis of a cohort comprising 5668 ethnic Arabs.
  • Principal Component Analysis (PCA) for population structure and ancestry inference.

Main Results:

  • Several novel genetic loci conferring risk for CAD and/or MI were identified.
  • Some identified loci demonstrated significant association in an independent validation cohort.
  • Principal Component Analysis indicated that the Saudi cohort shares genetic similarities with European populations (CEU and TSI).

Conclusions:

  • The study successfully identified genetic risk factors for myocardial infarction and coronary artery disease in the Saudi Arabian population.
  • These findings contribute to understanding the genetic architecture of cardiovascular disease in Middle Eastern populations.
  • The genetic similarity to European populations suggests potential shared genetic risk factors and warrants further investigation.

More Related Videos

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation07:15

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation

Published on: January 16, 2019

11.5K
Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease09:34

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

35.0K

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
83
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
70
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.4K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
61
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
16.4K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
61